By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Medivation, Inc. 

525 Market Street
36th Floor
San Francisco  California  94105  U.S.A.
Phone: 415-543-3470 Fax: 415-543-3411


SEARCH JOBS

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial.

For more information, please visit us at http://www.medivation.com/

Key Statistics


Email: info@medivation.com
Ownership: Public

Web Site: Medivation, Inc.
Employees: 18
Symbol: MDVN
 





Collaborations

Pfizer 





Company News
Astellas Pharma Inc. (ALPMY) And Medivation, Inc. (MDVN) Announce New Enzalutamide Data Presented During Plenary Presentations At The 2015 European Association Of Urology Congress 3/24/2015 9:42:26 AM
Medivation, Inc. (MDVN) Release: New Enzalutamide Data To Be Presented In Late Breaking News Plenary Session At European Association Of Urology Congress 3/17/2015 1:04:23 PM
Medivation, Inc. (MDVN) Reports Fourth Quarter And Full Year 2014 Financial Results And Provides Corporate Update 2/26/2015 11:47:13 AM
Medivation, Inc. (MDVN) Announces Participation At Upcoming Investor Conference 2/25/2015 1:56:04 PM
Medivation, Inc. (MDVN) Announces Fourth Quarter And Year-End 2014 Financial Results Teleconference On February 25, 2015 2/11/2015 3:18:00 PM
Medivation, Inc. (MDVN) Release: Enzalutamide Phase 2 Terrain Trial Demonstrated Statistically Significant Increase In PFS As Compared To Bicalutamide In Metastatic Prostate Cancer 1/22/2015 11:22:58 AM
Medivation, Inc. (MDVN) Exercises License Option For Pidilizumab 12/24/2014 10:11:08 AM
Biotech Predictions for Large Cap Firms Include Medivation, Inc. (MDVN), Gilead Sciences, Inc. (GILD) 12/18/2014 12:15:08 PM
Medivation, Inc. (MDVN) Announces Participation At Upcoming Investor Conference 12/18/2014 9:55:25 AM
Medivation, Inc. (MDVN) And Astellas Pharma Inc. (ALPMY) Phase 3 PREVAIL Trial Named Clinical Advance Of The Year By SCRIP 12/12/2014 11:04:46 AM
12345678910...
//-->